Swiss National Bank raised its position in ABIOMED, Inc. (NASDAQ:ABMD) by 2.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,300 shares of the medical equipment provider’s stock after purchasing an additional 1,700 shares during the quarter. Swiss National Bank owned 0.16% of ABIOMED worth $13,362,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. Crow Point Partners LLC bought a new position in ABIOMED in the 4th quarter worth about $120,000. Cerebellum GP LLC bought a new position in ABIOMED in the 4th quarter worth about $127,000. Advisor Partners LLC bought a new position in ABIOMED in the 4th quarter worth about $209,000. SeaCrest Wealth Management LLC bought a new position in ABIOMED in the 4th quarter worth about $183,000. Finally, Flagship Harbor Advisors LLC bought a new position in ABIOMED in the 4th quarter worth about $242,000. 86.99% of the stock is currently owned by institutional investors.
ABIOMED, Inc. (NASDAQ:ABMD) opened at $267.74 on Tuesday. ABIOMED, Inc. has a one year low of $114.28 and a one year high of $270.47. The stock has a market cap of $11,854.94, a P/E ratio of 135.22, a PEG ratio of 3.55 and a beta of 0.36.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The firm had revenue of $154.00 million for the quarter, compared to the consensus estimate of $154.00 million. During the same period last year, the firm earned $0.34 earnings per share. The company’s quarterly revenue was up 34.9% on a year-over-year basis. equities analysts expect that ABIOMED, Inc. will post 2.39 EPS for the current fiscal year.
A number of research firms have recently issued reports on ABMD. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Jefferies Group increased their price objective on shares of ABIOMED to $250.00 and gave the company a “buy” rating in a research note on Friday, January 12th. SunTrust Banks reiterated a “buy” rating and set a $370.00 price objective on shares of ABIOMED in a research note on Friday. Zacks Investment Research upgraded shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price objective on the stock in a research note on Monday, October 30th. Finally, Leerink Swann increased their price objective on shares of ABIOMED to $300.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. ABIOMED presently has an average rating of “Buy” and an average target price of $288.86.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/20/abiomed-inc-abmd-position-increased-by-swiss-national-bank.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.